Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal

March 11, 2025
, 5:53 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio in 2021. 2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma.

The post Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal appeared first on MedCity News.

Leave a Replay

How the American Cancer Society Is Using LLMs to Accelerate Research

Lantern Unveils Savings Methodology to Increase Transparency for Specialty Care Pricing

AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal

Leave a Replay

Related Posts

How the American Cancer Society Is Using LLMs to Accelerate Research

Lantern Unveils Savings Methodology to Increase Transparency for Specialty Care Pricing

AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us